Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

A suppressive oligodeoxynucleotide expressing TTAGGG motifs modulates cellular energetics through the mTOR signaling pathway.

Yazar V, Kilic G, Bulut O, Canavar Yildirim T, Yagci FC, Aykut G, Klinman DM, Gursel M, Gursel I.

Int Immunol. 2019 Oct 21. pii: dxz059. doi: 10.1093/intimm/dxz059. [Epub ahead of print]

PMID:
31633763
2.

Type I IFN-related NETosis in ataxia telangiectasia and Artemis deficiency.

Gul E, Sayar EH, Gungor B, Eroglu FK, Surucu N, Keles S, Guner SN, Findik S, Alpdundar E, Ayanoglu IC, Kayaoglu B, Geckin BN, Sanli HA, Kahraman T, Yakicier C, Muftuoglu M, Oguz B, Cagdas Ayvaz DN, Gursel I, Ozen S, Reisli I, Gursel M.

J Allergy Clin Immunol. 2018 Jul;142(1):246-257. doi: 10.1016/j.jaci.2017.10.030. Epub 2017 Nov 16.

PMID:
29155101
3.

Circulating LL37 targets plasma extracellular vesicles to immune cells and intensifies Behçet's disease severity.

Kahraman T, Gucluler G, Simsek I, Yagci FC, Yildirim M, Ozen C, Dinc A, Gursel M, Ikromzoda L, Sutlu T, Gay S, Gursel I.

J Extracell Vesicles. 2017 Feb 28;6(1):1284449. doi: 10.1080/20013078.2017.1284449. eCollection 2017.

4.

Effect of egg storage duration and brooding temperatures on chick growth, intestine morphology and nutrient transporters.

Yalcin S, Gursel I, Bilgen G, Horuluoglu BH, Gucluer G, Izzetoglu GT.

Animal. 2017 Oct;11(10):1791-1797. doi: 10.1017/S1751731117000404. Epub 2017 Feb 21.

PMID:
28219464
5.

Impaired toll like receptor-7 and 9 induced immune activation in chronic spinal cord injured patients contributes to immune dysfunction.

Gucluler G, Adiguzel E, Gungor B, Kahraman T, Gursel M, Yilmaz B, Gursel I.

PLoS One. 2017 Feb 7;12(2):e0171003. doi: 10.1371/journal.pone.0171003. eCollection 2017.

6.

Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development.

Bayyurt B, Tincer G, Almacioglu K, Alpdundar E, Gursel M, Gursel I.

J Control Release. 2017 Feb 10;247:134-144. doi: 10.1016/j.jconrel.2017.01.004. Epub 2017 Jan 7.

PMID:
28069554
7.

Efficient production and enhanced tumor delivery of engineered extracellular vesicles.

Watson DC, Bayik D, Srivatsan A, Bergamaschi C, Valentin A, Niu G, Bear J, Monninger M, Sun M, Morales-Kastresana A, Jones JC, Felber BK, Chen X, Gursel I, Pavlakis GN.

Biomaterials. 2016 Oct;105:195-205. doi: 10.1016/j.biomaterials.2016.07.003. Epub 2016 Jul 6.

8.

Development of CpG ODN Based Vaccine Adjuvant Formulations.

Gursel M, Gursel I.

Methods Mol Biol. 2016;1404:289-98. doi: 10.1007/978-1-4939-3389-1_20.

PMID:
27076306
9.

Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine.

Fais S, O'Driscoll L, Borras FE, Buzas E, Camussi G, Cappello F, Carvalho J, Cordeiro da Silva A, Del Portillo H, El Andaloussi S, Ficko Trček T, Furlan R, Hendrix A, Gursel I, Kralj-Iglic V, Kaeffer B, Kosanovic M, Lekka ME, Lipps G, Logozzi M, Marcilla A, Sammar M, Llorente A, Nazarenko I, Oliveira C, Pocsfalvi G, Rajendran L, Raposo G, Rohde E, Siljander P, van Niel G, Vasconcelos MH, Yáñez-Mó M, Yliperttula ML, Zarovni N, Zavec AB, Giebel B.

ACS Nano. 2016 Apr 26;10(4):3886-99. doi: 10.1021/acsnano.5b08015. Epub 2016 Mar 15. Review.

PMID:
26978483
10.

Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides.

Bayik D, Gursel I, Klinman DM.

Pharmacol Res. 2016 Mar;105:216-25. doi: 10.1016/j.phrs.2015.11.010. Epub 2016 Jan 15. Review.

11.

Intestinal Microbiota in Patients with Spinal Cord Injury.

Gungor B, Adiguzel E, Gursel I, Yilmaz B, Gursel M.

PLoS One. 2016 Jan 11;11(1):e0145878. doi: 10.1371/journal.pone.0145878. eCollection 2016.

12.

Egg storage duration and hatch window affect gene expression of nutrient transporters and intestine morphological parameters of early hatched broiler chicks.

Yalcin S, Gursel I, Bilgen G, Izzetoglu GT, Horuluoglu BH, Gucluer G.

Animal. 2016 May;10(5):805-11. doi: 10.1017/S175173111500261X. Epub 2015 Dec 7.

PMID:
26639350
13.

Biological properties of extracellular vesicles and their physiological functions.

Yáñez-Mó M, Siljander PR, Andreu Z, Zavec AB, Borràs FE, Buzas EI, Buzas K, Casal E, Cappello F, Carvalho J, Colás E, Cordeiro-da Silva A, Fais S, Falcon-Perez JM, Ghobrial IM, Giebel B, Gimona M, Graner M, Gursel I, Gursel M, Heegaard NH, Hendrix A, Kierulf P, Kokubun K, Kosanovic M, Kralj-Iglic V, Krämer-Albers EM, Laitinen S, Lässer C, Lener T, Ligeti E, Linē A, Lipps G, Llorente A, Lötvall J, Manček-Keber M, Marcilla A, Mittelbrunn M, Nazarenko I, Nolte-'t Hoen EN, Nyman TA, O'Driscoll L, Olivan M, Oliveira C, Pállinger É, Del Portillo HA, Reventós J, Rigau M, Rohde E, Sammar M, Sánchez-Madrid F, Santarém N, Schallmoser K, Ostenfeld MS, Stoorvogel W, Stukelj R, Van der Grein SG, Vasconcelos MH, Wauben MH, De Wever O.

J Extracell Vesicles. 2015 May 14;4:27066. doi: 10.3402/jev.v4.27066. eCollection 2015.

14.

Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings.

Gungor B, Yagci FC, Gursel I, Gursel M.

Oncoimmunology. 2014 Jul 3;3(7):e950166. eCollection 2014.

15.

Enhanced immunostimulatory activity of cyclic dinucleotides on mouse cells when complexed with a cell-penetrating peptide or combined with CpG.

Yildiz S, Alpdundar E, Gungor B, Kahraman T, Bayyurt B, Gursel I, Gursel M.

Eur J Immunol. 2015 Apr;45(4):1170-9. doi: 10.1002/eji.201445133. Epub 2015 Feb 4.

16.

CpG ODN nanorings induce IFNα from plasmacytoid dendritic cells and demonstrate potent vaccine adjuvant activity.

Gungor B, Yagci FC, Tincer G, Bayyurt B, Alpdundar E, Yildiz S, Ozcan M, Gursel I, Gursel M.

Sci Transl Med. 2014 May 7;6(235):235ra61. doi: 10.1126/scitranslmed.3007909.

17.

Plasmacytoid dendritic cell response to CpG ODN correlates with CXCL16 expression and is inhibited by ox-LDL.

Gursel M, Klinman DM, Gursel I.

Mediators Inflamm. 2013;2013:312590. doi: 10.1155/2013/312590. Epub 2013 Nov 4.

18.

Suppression of B-cell activation and IgE, IgA, IgG1 and IgG4 production by mammalian telomeric oligonucleotides.

Sackesen C, van de Veen W, Akdis M, Soyer O, Zumkehr J, Ruckert B, Stanic B, Kalaycı O, Alkan SS, Gursel I, Akdis CA.

Allergy. 2013;68(5):593-603. doi: 10.1111/all.12133. Epub 2013 Mar 9.

PMID:
23480796
19.

Immunogenicity and protective efficacy of the recombinant Pasteurella lipoprotein E and outer membrane protein H from Pasteurella multocida A:3 in mice.

Okay S, Özcengiz E, Gürsel I, Özcengiz G.

Res Vet Sci. 2012 Dec;93(3):1261-5. doi: 10.1016/j.rvsc.2012.05.011. Epub 2012 Jun 20.

PMID:
22727197
20.

The effects of an insertion in the 5'UTR of the AMCase on gene expression and pulmonary functions.

Birben E, Sackesen C, Kazani S, Tincer G, Karaaslan C, Durgunsu B, Gürsel I, Wechsler ME, Israel E, Kalayci O.

Respir Med. 2011 Aug;105(8):1160-9. doi: 10.1016/j.rmed.2011.03.017. Epub 2011 Apr 20.

21.

Immunostimulatory activity of polysaccharide-poly(I:C) nanoparticles.

Tincer G, Yerlikaya S, Yagci FC, Kahraman T, Atanur OM, Erbatur O, Gursel I.

Biomaterials. 2011 Jun;32(18):4275-82. doi: 10.1016/j.biomaterials.2011.01.028. Epub 2011 Apr 2.

PMID:
21459434
22.

Differential immune activation following encapsulation of immunostimulatory CpG oligodeoxynucleotide in nanoliposomes.

Erikçi E, Gursel M, Gürsel I.

Biomaterials. 2011 Feb;32(6):1715-23. doi: 10.1016/j.biomaterials.2010.10.054. Epub 2010 Nov 26.

PMID:
21112627
23.

Mammalian telomeric DNA suppresses endotoxin-induced uveitis.

Yagci FC, Aslan O, Gursel M, Tincer G, Ozdamar Y, Karatepe K, Akcali KC, Gursel I.

J Biol Chem. 2010 Sep 10;285(37):28806-11. doi: 10.1074/jbc.M110.125948. Epub 2010 Jul 14.

24.

Biosorption of phenol and 2-chlorophenol by Funalia trogii pellets.

Bayramoglu G, Gursel I, Tunali Y, Arica MY.

Bioresour Technol. 2009 May;100(10):2685-91. doi: 10.1016/j.biortech.2008.12.042. Epub 2009 Jan 30.

PMID:
19186052
25.

CpG-mediated changes in gene expression in murine spleen cells identified by microarray analysis.

Klaschik S, Gursel I, Klinman DM.

Mol Immunol. 2007 Feb;44(6):1095-104. Epub 2006 Aug 22.

PMID:
16930709
26.

CXCL16 influences the nature and specificity of CpG-induced immune activation.

Gursel M, Gursel I, Mostowski HS, Klinman DM.

J Immunol. 2006 Aug 1;177(3):1575-80.

27.

Therapeutic potential of oligonucleotides expressing immunosuppressive TTAGGG motifs.

Klinman DM, Gursel I, Klaschik S, Dong L, Currie D, Shirota H.

Ann N Y Acad Sci. 2005 Nov;1058:87-95. Review.

PMID:
16394128
28.

Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock.

Shirota H, Gursel I, Gursel M, Klinman DM.

J Immunol. 2005 Apr 15;174(8):4579-83.

29.
30.

Use of CpG oligodeoxynucleotides as immune adjuvants.

Klinman DM, Currie D, Gursel I, Verthelyi D.

Immunol Rev. 2004 Jun;199:201-16. Review.

PMID:
15233736
31.

Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides.

Ishii KJ, Gursel I, Gursel M, Klinman DM.

Curr Opin Mol Ther. 2004 Apr;6(2):166-74.

PMID:
15195929
32.

Regulation of CpG-induced immune activation by suppressive oligodeoxynucleotides.

Klinman DM, Zeuner R, Yamada H, Gursel M, Currie D, Gursel I.

Ann N Y Acad Sci. 2003 Dec;1002:112-23.

PMID:
14751829
33.

Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9.

Takeshita F, Gursel I, Ishii KJ, Suzuki K, Gursel M, Klinman DM.

Semin Immunol. 2004 Feb;16(1):17-22. Review.

PMID:
14751759
34.

Antitumor therapy with bacterial DNA and toxin: complete regression of established tumor induced by liposomal CpG oligodeoxynucleotides plus interleukin-13 cytotoxin.

Ishii KJ, Kawakami K, Gursel I, Conover J, Joshi BH, Klinman DM, Puri RK.

Clin Cancer Res. 2003 Dec 15;9(17):6516-22.

35.

Immunotherapeutic applications of CpG-containing oligodeoxynucleotides.

Klinman DM, Ishii KJ, Gursel M, Gursel I, Takeshita S, Takeshita F.

Drug News Perspect. 2000 Jun;13(5):289-96.

PMID:
12937643
36.

Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation.

Gursel I, Gursel M, Yamada H, Ishii KJ, Takeshita F, Klinman DM.

J Immunol. 2003 Aug 1;171(3):1393-400.

37.

Reduction of surgery-induced peritoneal adhesions by continuous release of streptokinase from a drug delivery system.

Yagmurlu A, Barlas M, Gursel I, Gokcora IH.

Eur Surg Res. 2003 Jan-Feb;35(1):46-9.

PMID:
12566787
38.

Effect of suppressive DNA on CpG-induced immune activation.

Yamada H, Gursel I, Takeshita F, Conover J, Ishii KJ, Gursel M, Takeshita S, Klinman DM.

J Immunol. 2002 Nov 15;169(10):5590-4.

39.

Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides.

Zeuner RA, Ishii KJ, Lizak MJ, Gursel I, Yamada H, Klinman DM, Verthelyi D.

Arthritis Rheum. 2002 Aug;46(8):2219-24.

40.

Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation.

Ishii KJ, Takeshita F, Gursel I, Gursel M, Conover J, Nussenzweig A, Klinman DM.

J Exp Med. 2002 Jul 15;196(2):269-74.

41.

CpG DNA: recognition by and activation of monocytes.

Klinman DM, Takeshita F, Gursel I, Leifer C, Ishii KJ, Verthelyi D, Gursel M.

Microbes Infect. 2002 Jul;4(9):897-901. Review.

PMID:
12106782
42.

Oxidative stress inhibits the phagocytosis of apoptotic cells that have externalized phosphatidylserine.

Anderson HA, Englert R, Gursel I, Shacter E.

Cell Death Differ. 2002 Jun;9(6):616-25.

43.

Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide.

Gürsel M, Verthelyi D, Gürsel I, Ishii KJ, Klinman DM.

J Leukoc Biol. 2002 May;71(5):813-20.

PMID:
11994506
44.

Chondroitin sulfate-coated polyhydroxyethyl methacrylate membrane prevents adhesion in full-thickness tendon tears of rabbits.

Güdemez E, Ekşioğlu F, Korkusuz P, Aşan E, Gürsel I, Hasirci V.

J Hand Surg Am. 2002 Mar;27(2):293-306.

PMID:
11901389
45.

Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells.

Takeshita F, Leifer CA, Gursel I, Ishii KJ, Takeshita S, Gursel M, Klinman DM.

J Immunol. 2001 Oct 1;167(7):3555-8.

46.
47.

Biodegradable polyhydroxyalkanoate implants for osteomyelitis therapy: in vitro antibiotic release.

Türesin F, Gürsel I, Hasirci V.

J Biomater Sci Polym Ed. 2001;12(2):195-207.

PMID:
11403236
48.

In vivo response to biodegradable controlled antibiotic release systems.

Korkusuz F, Korkusuz P, Ekşioĝlu F, Gürsel I, Hasirci V.

J Biomed Mater Res. 2001 May;55(2):217-28.

PMID:
11255173
49.

In vivo application of biodegradable controlled antibiotic release systems for the treatment of implant-related osteomyelitis.

Gürsel I, Korkusuz F, Türesin F, Alaeddinoglu NG, Hasirci V.

Biomaterials. 2001 Jan;22(1):73-80.

PMID:
11085386
50.

Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety.

Klinman DM, Kamstrup S, Verthelyi D, Gursel I, Ishii KJ, Takeshita F, Gursel M.

Springer Semin Immunopathol. 2000;22(1-2):173-83. Review. No abstract available.

PMID:
10944812

Supplemental Content

Loading ...
Support Center